The Effects of Conditioned Medium Derived from Mesenchymal Stem Cells Cocultured with Hepatocytes on Damaged Hepatocytes and Acute Liver Failure in Rats.
The Effects of Conditioned Medium Derived from Mesenchymal Stem Cells Cocultured with Hepatocytes on Damaged Hepatocytes and Acute Liver Failure in Rats.
复制标题
间充质干细胞与肝细胞共培养条件培养基对大鼠肝细胞损伤及急性肝衰竭的影响
DOI：
10.1155/2018/9156560
复制
发表时间：
2018
影响因子：
4.3
通讯作者：
Zhang S
中科院分区：
文献类型：
--
作者：
Chen L;Zhang J;Yang L;Zhang G;Wang Y;Zhang S
间充质干细胞（MSC）和肝细胞是两种有吸引力的基于细胞的治疗急性肝衰竭（ALF）的来源。骨髓间充质干细胞与肝细胞联合移植可提高治疗ALF的疗效。然而，来自与肝细胞共培养的MSC的条件培养基（CM）的治疗潜力（MSC-H-CM）仍不清楚。本研究的目的是研究MSC-H-CM对体外受损肝细胞和体内D-氨基半乳糖诱导的ALF的影响。在MSC-H-CM中培养的L02细胞经D-半乳糖胺处理后，其细胞活力和总蛋白合成均高于MSC-CM、肝细胞来源的CM（H-CM）、MSC-CM + H-CM和非条件培养基（NCM）。损伤的L02细胞在MSC-H-CM中培养的上清液中乳酸脱氢酶和天冬氨酸转氨酶水平低于在其他类型CM中培养的L02细胞。MSC-H-CM处理后观察到凋亡细胞百分比最低。当将CM注射到ALF大鼠的尾静脉时，MSC-H-CM在阻止肝损伤生物标志物的释放和促进肝脏结构的恢复方面最成功。在第一次治疗后7天，在MSC-H-CM治疗的大鼠中观察到最大的存活率。我们的研究结果表明，MSC-H-CM的交付可能是一种新的策略，整合肝细胞和MSC治疗ALF的治疗潜力。
Mesenchymal stem cells (MSCs) and hepatocytes are two attractive sources of cell-based therapies for acute liver failure (ALF). The cotransplantation of hepatocytes with MSCs can improve the therapeutic performance for the treatment of ALF. However, the therapeutic potential of conditioned medium (CM) derived from MSCs cocultured with hepatocytes (MSC-H-CM) remains unclear. The purpose of this study was to investigate the effects of MSC-H-CM on damaged hepatocytes in vitro and on D-galactosamine-induced ALF in vivo. D-Galactosamine-treated L02 cells cultured in MSC-H-CM exhibited higher of cell viability and total protein synthesis than L02 cells cultured in MSC-CM, CM derived from hepatocytes (H-CM), MSC-CM + H-CM, or with nonconditioned medium (NCM). Lactate dehydrogenase and aspartate aminotransferase levels were lower in the supernatant of damaged L02 cells cultured in MSC-H-CM than in that of L02 cells cultured in other types of CM. The lowest percentage of apoptotic cells was observed after the MSC-H-CM treatment. When CM was injected into the tail vein of rats with ALF, MSC-H-CM was the most successful at preventing the release of liver injury biomarkers and in promoting the recovery of liver structure. The greatest survival rate 7 days after the first treatment was observed in the MSC-H-CM-treated rats. Our results reveal that the delivery of MSC-H-CM could be a novel strategy for integrating the therapeutic potentials of hepatocytes and MSCs for the treatment of ALF.
登录
查看更多内容
影响因子：
7.5
作者：
Chen G;Jin Y;Shi X;Qiu Y;Zhang Y;Cheng M;Wang X;Chen C;Wu Y;Jiang F;Li L;Zhou H;Fu Q;Liu X
通讯作者：
Liu X
影响因子：
4.3
作者：
Chang, Wen-Ju;Song, Lu-Jun;Qin, Xin-Yu
通讯作者：
Qin, Xin-Yu
源自人类月经血液细胞的外泌体减轻了暴发性肝衰竭。
影响因子：
7.5
作者：
Chen L;Xiang B;Wang X;Xiang C
通讯作者：
Xiang C
影响因子：
4
作者：
Fouraschen, Suomi M. G.;Pan, Qiuwei;van der Laan, Luc J. W.
通讯作者：
van der Laan, Luc J. W.
影响因子：
5.2
作者：
Banas, Agnieszka;Teratani, Takumi;Ochiya, Takahiro
通讯作者：
Ochiya, Takahiro